In a study by Cox et al. moDCs generated in the presence of IFN-α and GM-CSF (IFN-DC), in combination with low doses of rituximab, were administered intranodally in a phase I clinical study in patients with follicular lymphoma. The gene discussed is IFNA1; the disease is follicular lymphoma.